웨어울프 테라퓨틱스(HOWL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.40 (+4.84%), 시가총액 $0.02B, 52주 범위 $0.43 ~ $2.19.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or m
웨어울프 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
웨어울프 테라퓨틱스의 현재 주가는 $0.40 (+4.84%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
웨어울프 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-media